Drilldown: Medicines

None (2)

Other values:

Search

None (34) · Dalmane (1) · Doral (1) · Halcion (1) · Lexotan (1) · Librium (1) · Mogadon (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) · Onfi (1) · ProSom (1) · Restoril (1) · Rohypnol (1) · Serax (1) · Tranxene (1) · Versed (1) · Xanax (1) · Zulresso (1) · Zurzuvae (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antipsychotic · Antiparkinsonian · Empathogen · Neuroleptic · Cathinone

Other values:

Search

None (1) · 5-HT2A agonist (12) · 5-HT2A agonist; long duration (1) · 5-HT2A agonist; MAO inhibitor (1) · 5-HT2A agonist; milder than other 2C-x (1) · 5-HT2A partial agonist (1) · Extremely potent 5-HT2A agonist; vasoconstrictor (1) · Extremely potent 5-HT2A agonist; very long duration (1) · Extremely potent GABAA positive allosteric modulator (1) · GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) · GABAA positive allosteric modulator (18) · GABAA positive allosteric modulator; low sedation (1) · GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) · GABAA positive allosteric modulator; very long half-life (1) · Potent 5-HT2A agonist (5) · Potent 5-HT2A agonist; no oral activity (1) · Potent 5-HT2A agonist; very long duration (1) · Synthetic neuroactive steroid (an analog of allopregnanolone), bioavailable orally unlike brexanolone. Positive allosteric modulator at GABA-A receptors including extrasynaptic δ-containing subtypes. (1) · Very potent 5-HT2A agonist; long duration (1)

None (48) · Postpartum depression (PPD) in adults (1) · Postpartum depression (PPD) in adults (FDA-approved 2023) (1) · '"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1)

None (48) · 0.25 mg (1) · 50 mg PO once daily with fatty food in the evening × 14 days (1) · Single 60-hour continuous IV infusion: 30 mcg/kg/h × 4h → 60 mcg/kg/h × 20h → 90 mcg/kg/h × 28h → 60 mcg/kg/h × 4h → 30 mcg/kg/h × 4h (1)

None (48) · 0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) · 100 mg/20 mL vial, single-use (1) · 20 mg, 25 mg, 30 mg capsules (1)

None (48) · 10 mg/d (1) · 50 mg/d × 14 d (1) · Single 60-hour course (1)

None (47) · insufflated (1) · Intravenous (continuous infusion in a REMS-certified facility) (1) · Oral (3) · PR (1)

None (47) · 30-60 min (immediate-release); 1-2 h (extended-release) (1) · 45-75 min (oral) (1) · Antidepressant effect within hours of infusion start; sustained at 30 days (1) · Day 3 of dosing in trials; sustained through day 45 (1)

None (47) · 14-day course; effect persists after discontinuation in trials (1) · 4-8 h (1) · 6 h (immediate-release); ~11 h (extended-release) (1) · Single infusion course (1)

None (47) · 11-13 h (immediate-release); 11-16 h (extended-release) (1) · Not well characterized (1) · ~16-23 hours (1) · ~9 hours (terminal) (1)

None (47) · 100% (IV) (1) · 80-90% oral (1) · Adequate (food-dependent, must take with fatty meal) (1) · Not well characterized (1)

None (47) · Category D'"`UNIQ--ref-0000006C-QINU`"' (1) · Limited data; avoid in pregnancy. Lactation: present in milk; consider risks (1) · Medicine is structurally identical to endogenous allopregnanolone; pregnancy considerations relate to breastfeeding during/after infusion. Limited data; brief interruption of breastfeeding considered (1) · Not established (1)

None (47) · Rx, Schedule IV (US) (1) · Rx; REMS program required (excessive sedation/loss of consciousness during infusion) (1) · Schedule IV (US) (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1)